Skills (28)
Research experience
-
Aug 2007–
presentResearch: Imperial College London
Imperial College London · Centre for Haematology · Imperial Molecular PatholgyUnited Kingdom · London -
Aug 2000–
Aug 2007Research: Royal Free & UCL Medical School
University College London · Academic HaematologyUnited Kingdom · London
Other
-
Scientific MembershipsBSHG
-
Journal RefereesBMC Cancer, Annals of Hematology, International Journal of Clinical Oncology, Leukemia
Questions and Answers (2) View all
-
Answer added in PCR26 Searching for a new real time PCR Machine - which one?Bang-for-buck, the Rotor-Gene every time, but I guess it's all down to your budget and need. If you want fast plate-based qPCR and don't need more tha... [more]
Publications (24) View all
-
Article: Combining BCR-ABL1 transcript levels at 3 and 6 months in chronic myeloid leukemia: implications for early intervention strategies.
[show abstract] [hide abstract]
ABSTRACT: Several groups have shown that that the BCR-ABL1 transcript level measured at 3 or 6 months after starting treatment with tyrosine kinase inhibitors strongly predicts for clinical outcomes for CML patients. In this work we asked whether the prognostic value of the 3-month transcript level could be improved by combining the 3- and 6- month results. We classified patients treated with imatinib and patients treated with dasatinib according to their transcript levels at 3 months and 6 months. The patients who met the 3-month landmark but failed the 6-month one had outcomes identical to those of patients who met both landmarks whereas the patients who failed the first landmark but met the second one had prognoses similar to those who failed both landmarks. In summary early intervention strategies can be based robustly just on the transcript level at 3 months. (ClinicalTrials.gov Identifier: NCT01460693).Blood 02/2013; · 9.90 Impact Factor -
Article: Dasatinib may overcome the negative prognostic impact of KIR2DS1 in newly diagnosed patients with chronic myeloid leukemia.
Blood 07/2012; 120(3):697-8. · 9.90 Impact Factor -
Article: BCR-ABL1 kinase domain mutations: methodology and clinical evaluation.
[show abstract] [hide abstract]
ABSTRACT: The introduction of tyrosine kinase inhibitors (TKIs), starting with imatinib and followed by second and third generation TKIs, has significantly changed the clinical management of patients with chronic myeloid leukemia (CML). Despite their unprecedented clinical success, a proportion of patients fail to achieve complete cytogenetic remission by 12 months of treatment (primary resistance) while others experience progressive resistance after an initial response (secondary resistance). BCR-ABL1 kinase domain (KD) mutations have been detected in a proportion of patients at the time of treatment failure, and therefore their identification and monitoring plays an important role in therapeutic decisions particularly when switching TKIs. When monitoring KD mutations in a clinical laboratory, the choice of method should take into account turnaround time, cost, sensitivity, specificity, and ability to accurately quantify the size of the mutant clone. In this article, we describe in a "manual" style the methods most widely used in our laboratory to monitor KD mutations in patients with CML including direct sequencing, D-HPLC, and pyrosequencing. Advantages, disadvantages, interpretation of results, and their clinical applications are reviewed for each method.American Journal of Hematology 03/2012; 87(3):298-304. · 4.67 Impact Factor -
Article: Analysis of BCR-ABL1 tyrosine kinase domain mutational spectra in primitive chronic myeloid leukemia cells suggests a unique mutator phenotype.
Leukemia: official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 10/2010; 24(10):1817-21. · 8.30 Impact Factor -
Article: hOCT1 transcript levels and single nucleotide polymorphisms as predictive factors for response to imatinib in chronic myeloid leukemia.
Leukemia: official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 06/2010; 24(6):1243-5. · 8.30 Impact Factor
